Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
Solid Tumors
DRUG: RC48-ADC
Maximal Tolerance Dose (MTD) of RC48-ADC, The dose level in which \>= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level., DLT will be evaluated on Day 28 during cycle 1
Safety (the drug safety as assessed by NCI-CTCAE v4.0), The drug safety as assessed by NCI-CTCAE v4.0, up to 2 years
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.